Spinout company Stroma Biosciences selected to take place in Accelerate@Babraham Start-up Programme | Wellcome-MRC Cambridge Stem Cell Institute
The way to improve survival rates among cancer patients could be through targetting normal cells
NOTCH1 drives immune-escape mechanisms in B cell malignancies | bioRxiv
Dr Ingo Ringshausen - Department of Haematology
Ingo Ringshausen (@i_ringshausen) / Twitter
Ingo RINGSHAUSEN | University of Cambridge, Cambridge | Cam | Stem Cell Institute | Research profile
Loop | Ingo Ringshausen
Ingo Ringshausen (@i_ringshausen) / Twitter
Ingo Ringshausen (@i_ringshausen) / Twitter
Dr Ingo Ringshausen | Wellcome-MRC Cambridge Stem Cell Institute
Spinouts, scientific synergies and old friends - Babraham Research Campus
Ingo Ringshausen (@i_ringshausen) / Twitter
Dr Ingo Ringshausen - Department of Haematology
Frontiers | ZAP-70 Shapes the Immune Microenvironment in B Cell Malignancies
Ingo Ringshausen (@i_ringshausen) / Twitter
Constitutively activated phosphatidylinositol-3 kinase (PI-3K) is involved in the defect of apoptosis in B-CLL: association with protein kinase Cδ by Ingo. - ppt download
Research Associate (Fixed Term) at the University of Cambridge, Department of Haematology - Redbionova
Ingo Ringshausen (@i_ringshausen) / Twitter
Ingo Ringshausen on Twitter: "Excellent talk indeed!" / Twitter
Dr Ingo Ringshausen | Wellcome-MRC Cambridge Stem Cell Institute
Ingo Ringshausen (@i_ringshausen) / Twitter
Dr Ingo Ringshausen | Wellcome-MRC Cambridge Stem Cell Institute
Targeting nearby 'normal' cells could improve survival rates - Department of Haematology
